Targeting this biochemical pathway may help develop new therapies for alleviating the symptoms of anxiety disorders.
The lab of Prof. Mike Fainzilber in the Institute’s Biomolecular Sciences Department has, for nearly two decades, studied the neuronal roles of proteins called importins. These proteins, found in all cells, shuttle molecules into the nucleus. The lab’s previous work focused on the peripheral nervous system (all nerve tissue in the body except the brain and spinal cord). Postdoctoral fellow Dr. Nicolas Panayotis, who joined the group in 2012, decided to find out whether any of the importins also play a role in the central nervous system, that is, the brain and spinal cord.
Panayotis and colleagues studied five lines of mice, genetically engineered by Prof. Michael Bader’s laboratory in the Max Delbrück Center for Molecular Medicine in Berlin, to lack genes from the alpha subfamily of importins. The researchers subjected these mice to a battery of behavioral tests and found that one line of mice – those lacking importin alpha-5 – stood out in a unique manner: They showed no anxiety in stressful situations, for example, when they were placed in large, exposed arenas or on a highly elevated, open platform.
The researchers then checked how these “calmer” mice differed from regular ones in terms of gene expression in certain brain regions involved in controlling anxiety. Computational analyses pointed to MeCP2, a regulatory gene known to affect anxiety behaviors. It turned out that importin alpha-5 was critical for enabling the entry of MeCP2 into the nuclei of neurons. Changes in the levels of MeCP2 in the nucleus, in turn, affected the levels of an enzyme involved in the production of a signaling molecule called S1P. In mice lacking importin alpha-5, MeCP2 failed to enter the nuclei of anxiety-controlling neurons, reducing S1P signaling and lowering anxiety.
After performing additional experiments to confirm that they had indeed discovered a new anxiety-regulating mechanism in the brain, the researchers searched for molecules that could modify this mechanism. They realized that drugs that modulate S1P signaling already exist; one such drug, fingolimod, is used to treat multiple sclerosis. When the researchers tested the effects of fingolimod on regular mice, these mice showed reduced anxiety, similarly to the genetically engineered mice lacking the importin alpha-5 gene. Moreover, the researchers found an earlier report from a clinical trial of fingolimod, according to which the drug had a calming effect on patients with multiple sclerosis. The new study might now help explain why this was the case.
“Our findings have opened up a new direction for research into the mechanisms of anxiety,” Panayotis says. “If we understand exactly how the circuitry that we’ve discovered controls anxiety, this may help develop new drugs, or direct the use existing ones, to alleviate its symptoms.”
Fainzilber: “Current drugs for anxiety are limited in their efficacy or have undesirable side effects, which also limit their usefulness. Our findings may help overcome these limitations. In follow-up research, we have already identified a number of drug candidates that target the newly discovered pathway.”
The study’s findings also shed new light on rare genetic disorders characterized by mutations in the MeCP2 gene: Rett syndrome and MeCP2 duplication syndrome. Both these disorders are characterized by anxiety, among other symptoms. Identifying the precise mechanisms responsible for the entry of MeCP2 into neurons’ nuclei may, in the future, help develop therapies for these two disorders.
We have already identified a number of drug candidates that target the newly discovered pathway
Taking part in this research were Dr. Shachar Y. Dagan, Anna Meshcheriakova, Dr. Sandip Koley, Dr. Letizia Marvaldi, Didi-Andreas Song and Prof. Eitan Reuveny of Weizmann’s Biomolecular Sciences Department; Dr. Anton Sheinin of Tel Aviv University; Prof. Izhak Michaelevski of Ariel University; Dr. Michael M. Tsoory of Weizmann’s Veterinary Resources Department; Dr. Franziska Rother, Prof. Enno Hartmann and Prof. Michael Bader of Max Delbrück Center for Molecular Medicine in Berlin, Germany; and Dr. Mayur Vadhvani and Prof. Britta Eickholt of Charité – Universitätsmedizin, also in Berlin.
Prof. Michael Fainzilber’s research is supported by the Laraine and Alan A. Fischer Laboratory for Biological Mass Spectometry; the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; the Zuckerman STEM Leadership Program; the Rising Tide Foundation; Mr. and Mrs. Lawrence Feis; the estate of Florence and Charles Cuevas; the estate of Lilly Fulop; and the European Research Council. Prof. Fainzilber is the incumbent of the Chaya Professorial Chair in Molecular Neuroscience.